Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Clinical and Translational Oncology
Erschienen in: Clinical and Translational Oncology 5/2016

21.10.2015 | Research Article

The effect of EGB on proliferation of gastric carcinoma SGC7901 cells

verfasst von: Y. Qian, L. Xia, W. Shi, JJ. Sun, YQ. Sun

Erschienen in: Clinical and Translational Oncology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

To investigate the effect of Ginkgo biloba extract (EGB) on the proliferation and cell cycles of gastric carcinoma SGC7901 cells, and make a preliminary exploration on possible molecular mechanisms associated with its inhibitory effect.

Methods

Human gastric carcinoma SGC7901 cells were cultured in vitro, and treated with various concentrations (100, 200, 300, 400 mg/L) of EGB for different incubation periods (24, 48 and 72 h). CCK-8 assay was used to detect cell proliferation and flow cytometry was performed to analyze the effect of EGB on cell cycles. In addition, mRNA and protein level of two cell cycle regulators cyclin D1 and c-myc in SGC7901 cells treated with EGB were determined using PCR and Western blot. And subcutaneous xenograft model of gastric carcinoma in nude mice was established to evaluate the anti-cancer effect of EGB in vivo.

Results

The proliferation of gastric carcinoma SGC7901 cells was inhibited by EGB in dose- and time-dependent manner. Flow cytometry showed cell cycle arrest in EGB-treated cells, with increased percentage of cells in G1 phase and decreased percentage in S stage. In addition, the mRNA and protein level of cyclin D1 and c-myc genes were significantly down-regulated in cells with EGB treatment with the concentration increasing.

Conclusion

EGB conferred an inhibitory effect on the proliferation of gastric carcinoma SGC7901 cells both in vitro and in vivo. The inhibitory effect was dose dependent and possibly depended on inhibiting cell cycle through G1 arrest induction by suppressing cyclin D1 and c-myc expression.
Literatur
1.
Gomez-Martin C, Concha A, Corominas JM, Garcia-Caballero T, Garcia-Garcia E, Iglesias M, et al. Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma. Clin Transl Oncol. 2011;13(9):636–51.CrossRefPubMed
2.
Zhou J, Teng XD. Clinicopathologic features of lymphoepithelioma-like gastric carcinoma and literature review. Zhonghua bing li xue za zhi Chin J Pathol. 2013;42(11):758–9.
3.
Zhu X, Li J. Gastric carcinoma in China: current status and future perspectives (review). Oncol lett. 2010;1(3):407–12.PubMedPubMedCentral
4.
Schneider R, Welt K, Aust W, Kluge R, Loster H, Fitzl G. Cardiovascular autonomic neuropathy in spontaneously diabetic rats with and without application of EGb 761. Histol Histopathol. 2010;25(12):1581–90.PubMed
5.
Rodriguez M, Ringstad L, Schafer P, Just S, Hofer HW, Malmsten M, et al. Reduction of atherosclerotic nanoplaque formation and size by Ginkgo biloba (EGb 761) in cardiovascular high-risk patients. Atherosclerosis. 2007;192(2):438–44.CrossRefPubMed
6.
Thanoon IA, Abdul-Jabbar HA, Taha DA. Oxidative stress and C-reactive protein in patients with cerebrovascular accident (ischaemic stroke): the role of Ginkgo biloba extract. Sultan Qaboos Univ Med J. 2012;12(2):197–205.CrossRefPubMedPubMedCentral
7.
Zhang Y, Chen AY, Li M, Chen C, Yao Q. Ginkgo biloba extract kaempferol inhibits cell proliferation and induces apoptosis in pancreatic cancer cells. J Surg Res. 2008;148(1):17–23.CrossRefPubMedPubMedCentral
8.
Yi SY, Nan KJ, Chen SJ. Effect of extract of Ginkgo biloba on doxorubicin-associated cardiotoxicity in patients with breast cancer. Chin J Integr Tradit West Med. 2008;28(1):68–70.
9.
Huang X, Whitworth CA, Rybak LP. Ginkgo biloba extract (EGb 761) protects against cisplatin-induced ototoxicity in rats. Otol Neurotol. 2007;28(6):828–33.CrossRefPubMed
10.
Hauns B, Haring B, Kohler S, Mross K, Unger C. Phase II study of combined 5-fluorouracil/Ginkgo biloba extract (GBE 761 ONC) therapy in 5-fluorouracil pretreated patients with advanced colorectal cancer. Phytother Res. 2001;15(1):34–8.CrossRefPubMed
11.
Hyun MH, Lee CH, Kim HJ, Tong Y, Park SS. Systematic review and meta-analysis of robotic surgery compared with conventional laparoscopic and open resections for gastric carcinoma. Br J Surg. 2013;100(12):1566–78.CrossRefPubMed
12.
Chen W, Ouyang XN, Lin QC. Study on the relationship between vascular endothelial growth factor and syndrome type of traditional Chinese medicine in patients with gastric carcinoma. Chin J Integr Tradit West Med. 2007;27(2):127–30.
13.
14.
Zeng JR, Wang CM, Zeng Y, Mo BW, Huang H. Experimental study on the effect of ginkgo bioba extract on the expression of heme oxygenase-1 in bronchial asthma. Chin J Appl Physiol. 2003;19(3):302–5.
15.
Ihl R. Gingko biloba extract EGb 761(R): clinical data in dementia. Int Psychogeriatr. 2012;24(Suppl 1):S35–40.CrossRefPubMed
16.
Shen J, Wang J, Zhao B, Hou J, Gao T, Xin W. Effects of EGb 761 on nitric oxide and oxygen free radicals, myocardial damage and arrhythmia in ischemia-reperfusion injury in vivo. Biochim Biophys Acta. 1998;1406(3):228–36.CrossRefPubMed
17.
Gautam J, Kushwaha P, Swarnkar G, Khedgikar V, Nagar GK, Singh D, et al. EGb 761 promotes osteoblastogenesis, lowers bone marrow adipogenesis and atherosclerotic plaque formation. Phytomedicine. 2012;19(12):1134–42.CrossRefPubMed
18.
Hao YR, Yang F, Cao J, Ou C, Zhang JJ, Yang C, et al. Ginkgo biloba extracts (EGb761) inhibits aflatoxin B1-induced hepatocarcinogenesis in Wistar rats. J Chin Med Mater. 2009;32(1):92–6.
19.
Ou C, Zheng HP, Su JJ, Cao J, Li GJ, Li LQ. Effect of Ginkgo biloba extract on the expressions of Cox-2 and GST-Pi in rats with hepatocellular carcinoma risk. Afr Heal Sci. 2014;14(1):37–48.CrossRef
20.
Brusselmans K, Vrolix R, Verhoeven G, Swinnen JV. Induction of cancer cell apoptosis by flavonoids is associated with their ability to inhibit fatty acid synthase activity. J Biol Chem. 2005;280(7):5636–45.CrossRefPubMed
21.
Kim KS, Rhee KH, Yoon JH, Lee JG, Lee JH, Yoo JB. Ginkgo biloba extract (EGb 761) induces apoptosis by the activation of caspase-3 in oral cavity cancer cells. Oral Oncol. 2005;41(4):383–9.CrossRefPubMed
22.
Pretner E, Amri H, Li W, Brown R, Lin CS, Makariou E, et al. Cancer-related overexpression of the peripheral-type benzodiazepine receptor and cytostatic anticancer effects of Ginkgo biloba extract (EGb 761). Anticancer Res. 2006;26(1A):9–22.PubMed
23.
Qi Y, Tu Y, Yang D, Chen Q, Xiao J, Chen Y, et al. Cyclin A but not cyclin D1 is essential for c-myc-modulated cell-cycle progression. J Cell Physiol. 2007;210(1):63–71.CrossRefPubMed
24.
Prall OW, Rogan EM, Musgrove EA, Watts CK, Sutherland RL. c-Myc or cyclin D1 mimics estrogen effects on cyclin E-Cdk2 activation and cell cycle reentry. Mol Cell Biol. 1998;18(8):4499–508.CrossRefPubMedPubMedCentral
Metadaten
Titel
The effect of EGB on proliferation of gastric carcinoma SGC7901 cells
verfasst von
Y. Qian
L. Xia
W. Shi
JJ. Sun
YQ. Sun
Publikationsdatum
21.10.2015
Verlag
Springer Milan
Erschienen in
Clinical and Translational Oncology / Ausgabe 5/2016
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-015-1399-3

Weitere Artikel der Ausgabe 5/2016

Clinical and Translational Oncology 5/2016 Zur Ausgabe

Brief Research Article

Bone marrow trephine biopsy involvement by lymphoma: pattern of involvement and concordance with flow cytometry, in 10 years from a single institution

Research Article

Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis

Research Article

The effect of slice thickness on target and organs at risk volumes, dosimetric coverage and radiobiological impact in IMRT planning

Research Article

Trends in lung cancer incidence by histologic subtype in the south of Spain, 1985–2012: a population-based study

Review Article

Non-coding RNAs deregulation in oral squamous cell carcinoma: advances and challenges

Research Article

Neutrophil to lymphocyte and platelet to lymphocyte ratios increase in ovarian tumors in the presence of frank stromal invasion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise